Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Bevacizumab(10mg/kg) plus FOLFIRI Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized
创建时间：
2009-08-15
